Your goal determines protocol intensity and duration
The FDA Category 2 peptide changes coming in 2026 represent a significant shift in the landscape of regenerative medicine
Although silencing the gene UL39 can limit the proliferation of oncolytic HSV-1 after injection, enhancing the safety of this oncolytic virus in clinical applications, the tumor-killing effect of this oncolytic virus is also restricted, requiring a larger dosage and multiple injections to achieve the desired effect
NAD+ is a coenzyme central to mitochondrial energy production and DNA repair
Gallen, Switzerland, in 2011
The Effect of Helicobacter pylori infection, aging, and consumption of Proton Pump inhibitor on fungal colonization in the stomach of dyspeptic patients